Immix Biopharma (IMMX) Corporate presentation summary

Disease background and unmet need

• AL amyloidosis affects over 30,000 relapsed/refractory patients in the U.S., with no FDA-approved therapies for those who relapse after first-line treatment.

• Current standard of care achieves only a 0-10% complete response rate in relapsed/refractory patients.

• Most patients require second-line therapy within a year, but available options are largely ineffective and not FDA-approved.

• Organ damage, especially to the heart and kidneys, is a major cause of morbidity and mortality.

Scientific platform and innovation

• NXC-201 is a BCMA-targeted CAR-T therapy designed to eliminate dysfunctional plasma cells producing toxic light chains.

• Proprietary engineering optimizes T-cell activation, reduces cytokine release, and enhances cytotoxicity.

• NXC-201 demonstrates rapid normalization of disease markers and deep hematologic responses.

Clinical trial results

• In the NEXICART-2 U.S. trial, NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis patients.

• Organ responses were observed in 100% of evaluable patients, including cardiac, renal, and liver improvements.

• Responses occurred rapidly, often within the first week of treatment.

• Safety profile showed no grade 5 treatment-related adverse events, short CRS duration, and no neurotoxicity.